title: Effect of verapamil on doxorubicin cardiotoxicity: altered muscle gene expression in cultured neonatal rat cardiomyocytes.
abstract: Verapamil reverses multidrug resistance acquired by cancer cells during treatment with chemotherapeutic agents such as doxorubicin by inhibiting the function of P-glycoprotein. Verapamil has also been suggested to potentiate the cardiotoxicity of doxorubicin. We have recently demonstrated that selective inhibition of cardiac muscle gene expression is among the earliest events in doxorubicin cardiotoxicity. To explore the influence of verapamil on doxorubicin cardiotoxicity, we evaluated [14C]-doxorubicin accumulation, cardiac muscle gene expression by Northern blot analysis, and ultrastructural changes in cultured cardiomyocytes in the presence and absence of verapamil. Treatment with a combination of doxorubicin and verapamil for 24 h did not augment doxorubicin accumulation in cardiomyocytes, although substantial augmentation of doxorubicin accumulation by verapamil in cardiac fibroblasts was observed. Further, treatment with verapamil for 24 h did not augment the decrease in expression of muscle genes induced by doxorubicin (myosin light chain 2 slow, troponin I, M isoform creatine kinase). However, we found that verapamil reduced alpha-actin gene expression in a direct, doxorubicin-independent manner. Furthermore, the effect of doxorubicin plus verapamil on alpha-actin gene expression was additive over a wide range of doxorubicin and verapamil concentrations, resulting in a selective augmentation of doxorubicin-induced inhibition of gene expression for this single muscle protein gene. This was reflected in a substantial increase in cardiac myocyte damage when treatment with verapamil and doxorubicin was compared to treatment with doxorubicin alone by thin section electron microscopy. This suggests a possible mechanism by which verapamil may potentiate doxorubicin cardiotoxicity.
authors.affiliation: Department of Medicine, Stanford University School of Medicine, California 94305.
authors.forename: H
authors.initials: H
authors.lastname: Akimoto
authors.forename: N A
authors.initials: NA
authors.lastname: Bruno
authors.forename: D L
authors.initials: DL
authors.lastname: Slate
authors.forename: M E
authors.initials: ME
authors.lastname: Billingham
authors.forename: S V
authors.initials: SV
authors.lastname: Torti
authors.forename: F M
authors.initials: FM
authors.lastname: Torti
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D015152:Blotting, Northern; D002250:Carbon Radioisotopes; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000378:metabolism / Q000633:toxicity*; D015870:Gene Expression / Q000187:drug effects*; D006321:Heart / Q000187:drug effects*; D007700:Kinetics; D008854:Microscopy, Electron; D009124:Muscle Proteins / Q000096:biosynthesis*; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure*; D012333:RNA, Messenger / Q000032:analysis / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D014700:Verapamil / Q000494:pharmacology*
chemical_list: D002250:Carbon Radioisotopes; D009124:Muscle Proteins; D012333:RNA, Messenger; D004317:Doxorubicin; D014700:Verapamil